bupropion has been researched along with Insulin Resistance in 6 studies
Bupropion: A propiophenone-derived antidepressant and antismoking agent that inhibits the uptake of DOPAMINE.
bupropion : An aromatic ketone that is propiophenone carrying a tert-butylamino group at position 2 and a chloro substituent at position 3 on the phenyl ring.
Insulin Resistance: Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Naltrexone/bupropion is an investigational combination for weight loss and maintenance in patients who are obese or have a BMI ≥ 27 kg/m(2) with comorbid diabetes, hypertension or hyperlipidemia." | 8.87 | Naltrexone/bupropion: an investigational combination for weight loss and maintenance. ( Gwinn, KM; Hurren, KM; Makowski, CT, 2011) |
| "Insulin resistance was also assessed at the end." | 6.71 | Weight gain and cardiovascular risk factors during smoking cessation with bupropion or nicotine. ( Alvarez, F; Botella-Carretero, JI; Cantarero, M; Escobar-Morreale, HF; García, G; Martín, I; Valero, AM; Varela, C, 2004) |
| " The aim of the present review is to summarize the current data on the eff ects of antiobesity drugs approved in Europe (orlistat, liraglutide 3 mg od and naltrexone/bupropion) on weight loss in patients with PCOS and to discuss their impact on the endocrine, reproductive and metabolic abnormalities of this population." | 4.98 | The Role of Antiobesity Agents in the Management of Polycystic Ovary Syndrome. ( Chatzis, P; Dinas, K; Makris, V; Pratilas, GC; Sotiriadis, A; Tziomalos, K, 2018) |
| "Naltrexone/bupropion is an investigational combination for weight loss and maintenance in patients who are obese or have a BMI ≥ 27 kg/m(2) with comorbid diabetes, hypertension or hyperlipidemia." | 4.87 | Naltrexone/bupropion: an investigational combination for weight loss and maintenance. ( Gwinn, KM; Hurren, KM; Makowski, CT, 2011) |
| "Insulin resistance was also assessed at the end." | 2.71 | Weight gain and cardiovascular risk factors during smoking cessation with bupropion or nicotine. ( Alvarez, F; Botella-Carretero, JI; Cantarero, M; Escobar-Morreale, HF; García, G; Martín, I; Valero, AM; Varela, C, 2004) |
| "Weight gain is cited as a primary reason for not trying to quit smoking." | 2.42 | Smoking cessation and weight gain. ( Fernández Pinilla, MC; Fernández-Cruz, A; Filozof, C, 2004) |
| "Liver from rats with non-alcoholic steatohepatitis (NASH) demonstrated significant higher TNF-α level, inflammatory cell infiltration, ballooning and steatosis which significantly ameliorated by BUP treatment." | 1.40 | Bupropion effects on high-fat diet-induced steatohepatitis and endothelial dysfunction in rats: role of tumour necrosis factor-alpha. ( abd Alzez, LF; Ahmed, M; El serafi, O; El-Bakly, WM; Zaki, AM, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chatzis, P | 1 |
| Tziomalos, K | 1 |
| Pratilas, GC | 1 |
| Makris, V | 1 |
| Sotiriadis, A | 1 |
| Dinas, K | 1 |
| Ahmed, M | 1 |
| El-Bakly, WM | 1 |
| Zaki, AM | 1 |
| abd Alzez, LF | 1 |
| El serafi, O | 1 |
| Stefanidis, A | 1 |
| Man Lee, CC | 1 |
| Brown, WA | 1 |
| Oldfield, BJ | 1 |
| Makowski, CT | 1 |
| Gwinn, KM | 1 |
| Hurren, KM | 1 |
| Botella-Carretero, JI | 1 |
| Escobar-Morreale, HF | 1 |
| Martín, I | 1 |
| Valero, AM | 1 |
| Alvarez, F | 1 |
| García, G | 1 |
| Varela, C | 1 |
| Cantarero, M | 1 |
| Filozof, C | 1 |
| Fernández Pinilla, MC | 1 |
| Fernández-Cruz, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| WhatsApp Embedded in Routine Service Delivery for Smoking Cessation: Effects on Success Rates in a Randomized Controlled Study[NCT03714971] | 127 participants (Actual) | Interventional | 2017-03-01 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for bupropion and Insulin Resistance
| Article | Year |
|---|---|
The Role of Antiobesity Agents in the Management of Polycystic Ovary Syndrome.
Topics: Androgens; Anti-Obesity Agents; Bupropion; Drug Combinations; Female; Humans; Insulin Resistance; Li | 2018 |
Naltrexone/bupropion: an investigational combination for weight loss and maintenance.
Topics: Anti-Obesity Agents; Bupropion; Diabetes Mellitus; Drug Therapy, Combination; Glycated Hemoglobin; H | 2011 |
Smoking cessation and weight gain.
Topics: Body Composition; Bupropion; Cardiovascular Diseases; Dopamine Uptake Inhibitors; Female; Humans; In | 2004 |
1 trial available for bupropion and Insulin Resistance
| Article | Year |
|---|---|
Weight gain and cardiovascular risk factors during smoking cessation with bupropion or nicotine.
Topics: Administration, Cutaneous; Adult; Aging; Blood Pressure; Bupropion; Cardiovascular Diseases; Diastol | 2004 |
2 other studies available for bupropion and Insulin Resistance
| Article | Year |
|---|---|
Bupropion effects on high-fat diet-induced steatohepatitis and endothelial dysfunction in rats: role of tumour necrosis factor-alpha.
Topics: Animals; Bupropion; Diet, High-Fat; Endothelium, Vascular; Fatty Liver; Insulin Resistance; Male; Ra | 2014 |
Improving efficacy of the adjustable gastric band: studies of the use of adjuvant approaches in a rodent model.
Topics: Adipose Tissue, Brown; Animals; Anti-Obesity Agents; Blood Glucose; Body Composition; Body Fat Distr | 2017 |